Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.
Benson AB 3rd, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, Kudrik F. Benson AB 3rd, et al. Among authors: hecht jr. Oncologist. 2017 Mar;22(3):241-e15. doi: 10.1634/theoncologist.2017-0024. Epub 2017 Feb 28. Oncologist. 2017. PMID: 28246206 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.
Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA Jr. Grothey A, et al. Among authors: hecht jr. Clin Cancer Res. 2018 Jan 15;24(2):316-325. doi: 10.1158/1078-0432.CCR-17-1558. Epub 2017 Oct 30. Clin Cancer Res. 2018. PMID: 29084918 Clinical Trial.
Male breast cancer.
Hecht JR, Winchester DJ. Hecht JR, et al. Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S25-30. Am J Clin Pathol. 1994. PMID: 7942610 Review.
86 results